Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

SELL
$59.06 - $75.72 $4,311 - $5,527
-73 Reduced 17.55%
343 $25,000
Q3 2023

Nov 13, 2023

SELL
$65.94 - $99.04 $131 - $198
-2 Reduced 0.48%
416 $28,000
Q2 2023

Aug 08, 2023

BUY
$62.68 - $95.05 $125 - $190
2 Added 0.48%
418 $39,000
Q4 2022

Feb 06, 2023

BUY
$30.35 - $53.15 $2,428 - $4,252
80 Added 23.81%
416 $20,000
Q3 2022

Nov 09, 2022

SELL
$31.97 - $49.37 $8,727 - $13,478
-273 Reduced 44.83%
336 $11,000
Q2 2022

Aug 04, 2022

BUY
$35.61 - $76.23 $16,772 - $35,904
471 Added 341.3%
609 $24,000
Q1 2022

Aug 23, 2022

BUY
$57.56 - $82.54 $172 - $247
3 Added 2.22%
138 $10,000
Q1 2022

Apr 14, 2022

SELL
$57.56 - $82.54 $1,381 - $1,980
-24 Reduced 15.09%
135 $9,000
Q4 2021

Feb 14, 2022

BUY
$72.5 - $100.68 $1,377 - $1,912
19 Added 13.57%
159 $12,000
Q3 2021

Nov 10, 2021

BUY
$90.24 - $124.05 $9,565 - $13,149
106 Added 311.76%
140 $13,000
Q2 2021

Aug 04, 2021

SELL
$93.66 - $139.27 $6,368 - $9,470
-68 Reduced 66.67%
34 $4,000
Q1 2021

May 05, 2021

BUY
$116.57 - $155.01 $1,515 - $2,015
13 Added 14.61%
102 $13,000
Q4 2020

Feb 04, 2021

BUY
$99.61 - $142.12 $5,976 - $8,527
60 Added 206.9%
89 $12,000
Q3 2020

Nov 09, 2020

SELL
$72.92 - $102.01 $1,968 - $2,754
-27 Reduced 48.21%
29 $3,000
Q2 2020

Aug 06, 2020

BUY
$55.75 - $92.75 $2,731 - $4,544
49 Added 700.0%
56 $5,000
Q4 2019

Feb 07, 2020

SELL
$77.66 - $99.74 $155 - $199
-2 Reduced 22.22%
7 $1,000
Q3 2019

Nov 01, 2019

BUY
$90.37 - $122.49 $271 - $367
3 Added 50.0%
9 $1,000
Q2 2019

Aug 08, 2019

BUY
$89.51 - $118.04 $537 - $708
6 New
6 $1,000
Q1 2018

May 01, 2018

SELL
$39.82 - $57.53 $159 - $230
-4 Closed
0 $0
Q4 2017

Feb 06, 2018

BUY
$46.49 - $60.51 $185 - $242
4
4 $0

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Glassman Wealth Services Portfolio

Follow Glassman Wealth Services and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glassman Wealth Services, based on Form 13F filings with the SEC.

News

Stay updated on Glassman Wealth Services with notifications on news.